Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Frank Dellanna, David Goldsmith, Andriy Krendyukov, Andreas Seidl, Nadja Höbel & Christian Combe. (2018) HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience. Drug Design, Development and Therapy 12, pages 9-14.
Read now
Read now
Valentina Perrone, Stefania Saragoni, Stefano Buda, Alessandro Broccoli & Luca Degli Esposti. (2016) Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars. Biologics: Targets and Therapy 10, pages 157-165.
Read now
Read now
Paul Declerck, Håkan Mellstedt & Silvio Danese. (2015) Biosimilars – terms of use. Current Medical Research and Opinion 31:12, pages 2325-2330.
Read now
Read now
Analia Rodriguez Garzotto, Oliver Heine, Matthew Turner, Francisco Rebollo Laserna & Andreas Lorenz. (2014) Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. Journal of Blood Medicine 5, pages 43-48.
Read now
Read now
Mary Lynn Davis-Ajami, Jun Wu, Katherine Downton, Emilie Ludeman & Virginia Noxon. (2014) Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics: Targets and Therapy 8, pages 155-167.
Read now
Read now
Alaa Bagalagel, Abdulaziz Mohammed, Karen MacDonald & Ivo Abraham. (2013) Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 3, pages 35-43.
Read now
Read now
Ivo Abraham, Diana Sun, Alaa Bagalagel, Ahmed Altyar, Abdulaziz Mohammed, Soba Tharmarajah & Karen MacDonald. (2013) Biosimilars in 3D. Bioengineered 4:4, pages 203-206.
Read now
Read now
Ivo Abraham, Soba Tharmarajah & Karen MacDonald. (2013) Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opinion on Drug Safety 12:2, pages 235-246.
Read now
Read now
Articles from other publishers (30)
Hailekiros Gebretsadik, Getu Kahsay, Erwin Adams & Ann Van Schepdael. (2023) A comprehensive review of capillary electrophoresis-based techniques for erythropoietin isoforms analysis. Journal of Chromatography A 1708, pages 464331.
Crossref
Crossref
Pere Gascón, David Goldsmith, Matti Aapro, Frank Dellanna, Altaher Esmael & Markus Zabransky. (2023) Epoetin alfa biosimilar (HX575): A review of 15 years’ post-approval clinical experience. Critical Reviews in Oncology/Hematology 181, pages 103894.
Crossref
Crossref
Sean AinsworthSean Ainsworth. 2020. Neonatal Formulary. Neonatal Formulary.
Eva Rahman Kabir, Shannon Sherwin Moreino & Mohammad Kawsar Sharif Siam. (2019) The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. Biomolecules 9:9, pages 410.
Crossref
Crossref
Fiorenzo Santoleri, Alessia Romagnoli & Alberto Costantini. (2019) Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital. Future Oncology 15:1, pages 45-51.
Crossref
Crossref
Sarfaraz K. NiaziSarfaraz K. Niazi. 2018. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
157
226
.
Sarfaraz K. NiaziSarfaraz K. Niazi. 2018. Biosimilarity. Biosimilarity
263
288
.
Yelena Y Janjigian, Marco Bissig, Giuseppe Curigliano, Jennifer Coppola & Mark Latymer. (2018) Talking to patients about biosimilars. Future Oncology 14:23, pages 2403-2414.
Crossref
Crossref
Matti Aapro, Andriy Krendyukov, Nadja Höbel, Andreas Seidl & Pere Gascón. (2018)
Development and 10-year history of a biosimilar: the example of Binocrit
®
. Therapeutic Advances in Medical Oncology 10, pages 175883591876841.
Crossref
Crossref
Constantinos E. Alifieris, Kyriakos Orfanakos, Aristina Papanota, George P. Stathopoulos, Nikolaos Sitaras & Dimitrios T. Trafalis. (2017) A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors. Journal of Cancer Research and Clinical Oncology 143:4, pages 717-725.
Crossref
Crossref
Jean Klastersky & Lissandra Dal Lago. (2017) Old age: An extra risk for febrile neutropenia?. Journal of Geriatric Oncology 8:2, pages 84-85.
Crossref
Crossref
Giovanni Rosti, Mario Petrini, Alberto Bosi, Piero Galieni, Daniele Bernardi, Gianfranco Giglio, Laura Dorotea, Brunangelo Falini, Elvira Scelzi, Enzo Veltri, Roberto Castelli, Chiara Longagnani, Tommaso Raggi & Federico Simonetti. (2016) Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Therapeutic Advances in Medical Oncology 9:1, pages 22-32.
Crossref
Crossref
Kamyar Kalantar-Zadeh. (2017) History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. American Journal of Nephrology 45:3, pages 235-247.
Crossref
Crossref
Theresa W. Chan, Niloofar Latifi, Anna Weiss & Sarah L. Blair. 2017. Surgical Emergencies in the Cancer Patient. Surgical Emergencies in the Cancer Patient
329
346
.
Jay B. Wish, Chaim Charytan, Glenn M. Chertow, Kamyar Kalantar-Zadeh, Alan S. Kliger, Robert J. Rubin, Jerry Yee & Steven Fishbane. (2016) Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases 68:6, pages 843-852.
Crossref
Crossref
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
1
22
.
Pere Gascon. (2015) The evolving role of biosimilars in haematology–oncology: a practical perspective. Therapeutic Advances in Hematology 6:6, pages 267-281.
Crossref
Crossref
Vittorio Perfetti, Simona Dalle Carbonare, Silvia Vecchio, Chiara Paglino, Simona Secondino, Michele Tringali, Paolo Pedrazzoli & Mirosa Dellagiovanna. (2015) Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience. PharmacoEconomics Italian Research Articles 17:1.
Crossref
Crossref
Merry Christie, David Peritt, Raul M. Torres, Theodore W. Randolph & John F. Carpenter. (2015) The Role of Protein Excipient in Driving Antibody Responses to Erythropoietin. Journal of Pharmaceutical Sciences 104:12, pages 4041-4055.
Crossref
Crossref
Adrian Covic & Ivo Abraham. (2015) State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. International Urology and Nephrology 47:9, pages 1529-1539.
Crossref
Crossref
H?ctor Garc?a-Nares, Mar?a Isabel Leyva-Carmona, Neftal? P?rez-Xochipa & Erwin Chiquete. (2015) Hypersensitivity reaction to a biosimilar insulin glargine ????????????????. Journal of Diabetes 7:2, pages 155-157.
Crossref
Crossref
Mario Thevis & Wilhelm Schänzer. (2014) Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of Pharmaceutical and Biomedical Analysis 101, pages 66-83.
Crossref
Crossref
Michael Hedenus, Heinz Ludwig, David H. Henry & Eduard Gasal. (2014) Pharmacovigilance in practice: erythropoiesis‐stimulating agents. Cancer Medicine 3:5, pages 1416-1429.
Crossref
Crossref
Roberto Castelli, Giorgio Lambertenghi Deliliers, Riccardo Colombo, Guido Moreo, Paolo Gallipoli & Giuseppe Pantaleo. (2014) Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Annals of Hematology 93:9, pages 1523-1529.
Crossref
Crossref
Ivo Abraham, Lucy Han, Diana Sun, Karen MacDonald & Matti Aapro. (2014) Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncology 10:9, pages 1599-1609.
Crossref
Crossref
Ali McBride. (2017) Evolving Biosimilars Marketplace. Hospital Pharmacy 49:1_suppl, pages 1-5.
Crossref
Crossref
Judith Genevieve Marin, Marianna Leung, Clifford Lo, Nicole W Tsao & Daniel J Martinusen. (2014) Efficacy and Safety Data of Subsequent Entry Biologics Pertinent to Nephrology Practice: A Systematic Review. Canadian Journal of Kidney Health and Disease 1, pages 34.
Crossref
Crossref
Savino Sciascia, Dario Roccatello, Chary Lopez-Pedrera & Maria Jose’ Cuadrado. 2014. Drugs Targeting B-Cells in Autoimmune Diseases. Drugs Targeting B-Cells in Autoimmune Diseases
277
284
.
Steven D. Lucio, James G. Stevenson & James M. Hoffman. (2013) Biosimilars: Implications for health-system pharmacists. American Journal of Health-System Pharmacy 70:22, pages 2004-2017.
Crossref
Crossref
Walter H. Hörl. (2013) Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease. Drugs 73:2, pages 117-130.
Crossref
Crossref